DNX Biopharmaceuticals and XL-protein Enter into a Shareholder Agreement to Develop and Commercialize Novel Long Acting Biopharmaceuticals.
Irvine, California, and Freising, Germany, February 1, 2016
On…
XL-protein and Easton Pharmaceutical sign license agreement to develop biopharmaceuticals using PASylation® technology
Freising, Germany, and Chengdu, P.R. China, December 17, 2015…
DNX and XL-protein Announce Collaboration to Develop Novel, Long-Acting Biopharmaceutical Products
New Half-Life Extension Platform Technology Will Support the…